WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 202710
CAS#: 627908-92-3 (free base)
Description: SU14813 is an oral, multitargeted tyrosine kinase inhibitor (TKI) targeting vascular endothelial growth factor receptors (VEGFR), platelet-derived growth factor receptors (PDGFR), KIT, and fms-like tyrosine kinase 3 (FLT-3) (1). SU14813 was developed as a next-generation TKI agent following sunitinib (SU11248) designed to demonstrate optimized pharmacokinetic (PK) and tolerability profiles. SU14813 demonstrated broad and potent antitumor activity equivalent to that of sunitinib, which resulted in tumor regression, growth arrest, growth delay, and prolonged survival in established xenograft cancer models in mice.
MedKoo Cat#: 202710
Name: SU14813
CAS#: 627908-92-3 (free base)
Chemical Formula: C23H27FN4O4
Exact Mass: 442.20163
Molecular Weight: 442.48
Elemental Analysis: C, 62.43; H, 6.15; F, 4.29; N, 12.66; O, 14.46
Related CAS #: 452105-23-6 (Z isomer) 627908-92-3 (free base) 849643-15-8 (maleate)
Synonym: SU14813; SU 14813; SU-14813; SU014813; SU-014813; SU 014813
IUPAC/Chemical Name: (S,Z)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-N-(2-hydroxy-3-morpholinopropyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide
InChi Key: CTNPALGJUAXMMC-PMFHANACSA-N
InChi Code: InChI=1S/C23H27FN4O4/c1-13-20(10-18-17-9-15(24)3-4-19(17)27-22(18)30)26-14(2)21(13)23(31)25-11-16(29)12-28-5-7-32-8-6-28/h3-4,9-10,16,26,29H,5-8,11-12H2,1-2H3,(H,25,31)(H,27,30)/b18-10-/t16-/m0/s1
SMILES Code: O=C(C1=C(C)NC(/C=C2C(NC3=C\2C=C(F)C=C3)=O)=C1C)NC[C@H](O)CN4CCOCC4
Appearance: white solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
| Biological target: | SU14813 is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT. |
| In vitro activity: | SU14813 inhibited cellular ligand-dependent phosphorylation of VEGFR-2 (transfected NIH 3T3 cells), PDGFR-β (transfected NIH 3T3 cells), KIT (Mo7e cells), and FLT3-internal tandem duplication (FLT3-ITD; MV4;11 cells) as well as FMS/CSF1R (transfected NIH 3T3 cells), another split-kinase RTK (Table 1). Furthermore, SU14813 inhibited VEGFR-2, PDGFR-β, and KIT phosphorylation in porcine aorta endothelial cells overexpressing these targets, with cellular IC50 values of 5.2, 9.9, and 11.2 nmol/L, respectively. Consistent with its cellular RTK inhibitory activities, SU14813 inhibited PDGF-dependent proliferation of NIH-3T3 cells overexpressing PDGFR-β, FLT3 ligand–dependent proliferation of OC1-AML5 human AML cells expressing wild-type FLT3, and autonomous proliferation of MV4;11 human AML cells expressing constitutively active mutant FLT3-ITD (Table 1). In contrast, SU14813 did not potently inhibit epidermal growth factor–dependent DNA synthesis in NIH 3T3 cells overexpressing EGFR, a nontarget RTK, verifying that its effects are RTK target specific (Table 1). Reference: Mol Cancer Ther. 2006 Jul;5(7):1774-82. https://mct.aacrjournals.org/content/5/7/1774.long |
| In vivo activity: | In xenograft models using human and rat tumor cells implanted in athymic or nonobese diabetic/severe combined immunodeficient mice, SU14813 exhibited dose-dependent antitumor efficacy, resulting in regression of 786-O (PDGFR, VEGFR-expressing) and MV4;11 (activated FLT3-dependent) tumors, growth arrest of Colo205 tumors, and growth delay of C6 (PDGFR-expressing) and MV522 tumors (Table 2). Representative study results using C6, MV4;11, and 786-O models are shown in Fig. 3. SU14813 was also evaluated in a physiologically relevant leukemia model in mice, in which MV4;11 human AML cells engraft and proliferate in the bone marrow. SU14813 treatment conferred an approximate doubling of survival time from 23 to 42 days at these dose levels (Table 3). Reference: Mol Cancer Ther. 2006 Jul;5(7):1774-82. https://mct.aacrjournals.org/content/5/7/1774.long |
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| DMSO | 54.0 | 122.04 | |
| DMF | 30.0 | 67.8 | |
| Ethanol | 0.1 | 0.23 | |
| PBS (pH 7.2) | 0.1 | 0.23 |
The following data is based on the product molecular weight 442.48 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | 1. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. PMID: 16891463. |
| In vitro protocol: | 1. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. PMID: 16891463. |
| In vivo protocol: | 1. Patyna S, Laird AD, Mendel DB, O'farrell AM, Liang C, Guan H, Vojkovsky T, Vasile S, Wang X, Chen J, Grazzini M, Yang CY, Haznedar JO, Sukbuntherng J, Zhong WZ, Cherrington JM, Hu-Lowe D. SU14813: a novel multiple receptor tyrosine kinase inhibitor with potent antiangiogenic and antitumor activity. Mol Cancer Ther. 2006 Jul;5(7):1774-82. doi: 10.1158/1535-7163.MCT-05-0333. PMID: 16891463. |
Related CAS#
452105-23-6 ( SU14813 double Z isomer)
627908-92-3 (SU1481free base);
849643-15-8 (SU1481 maleate)
